Malignant Neoplasm of Unknown Primary

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

Neratinib suppresses anchorage-independent growth in transduced HPNE cells with the variant in a concentration-dependent manner (Figure 6B–C) with complete inhibition at a concentration of 0.5 µM (Fig… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion. Afatinib monotherapy resulted… (full text at CIViC)

PMID 26559459 · Li et al., 2015 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In an in vitro study, an esophageal squamous cell carcinoma (ESCC) cell line KYSE150 expressing ERBB3 (HER3) D297Y mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib trea… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agen… (full text at CIViC)

PMID 25216528 · Thomas et al., 2014 · Open in CIViC

In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

In an in vitro study, an head and neck squamous cell carcinoma (HNSCC) cell line KYSE270 expressing ERBB3 (HER3) R1202W mutation was associated with insensitivity to cetuximab and erlotinib treatments… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

Preventing HER4 cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response… (full text at CIViC)

PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC

siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.

PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC

This retrospective preclinical study assessed the efficacy of afatinib towards head-and-neck squamous cell carcinoma (HNSCC) human cell lines expressing ERBB4 (HER4) G1109C mutation. According to the … (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In an in vitro study, a head and neck squamous cell carcinoma cell line SAS expressing ERBB4 (HER4) G1109C was associated with insensitivity to erlotinib treatment (IC50=1.47uM). Resistance was determ… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoter… (full text at CIViC)

PMID 26894620 · Bauer et al., 2017 · Open in CIViC

A 53 year old female patient had PTC treated with surgery and multiple brain metastases. TERT c.-124C.T mutation and ETV6::NTRK2 fusion was found in pleural biopsy and cerebellar resection specimens.… (full text at CIViC)

PMID 35171659 · Park et al., 2022 · Open in CIViC

Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) h… (full text at CIViC)

PMID 26784937 · Prasad et al., 2016 · Open in CIViC

mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-depende… (full text at CIViC)

PMID 24253377 · Okazaki et al., 2014 · Open in CIViC

1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between tr… (full text at CIViC)

PMID 24989892 · Norton et al., 2014 · Open in CIViC

1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survi… (full text at CIViC)

PMID 24989892 · Norton et al., 2014 · Open in CIViC

In a retrospective study of 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, FGF19 copy-number gain (defined as ≥5 copies) was detected in 2/6 (33.3%) patients with complete… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In a study with a panel of 40 HCC cell lines and 30 HCC PDX model showed that FGF19 expression is a predictive biomarker for H3B-6527. H3B-6527 is a highly selective covalent FGFR4 inhibitor.

PMID 29247039 · Joshi et al., 2017 · Open in CIViC

In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once … (full text at CIViC)

PMID 31575541 · Kim et al., 2019 · Open in CIViC

FGF3/FGF4 amplification was observed in around 2% of HCCs. Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastas… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

In a retrospective analysis of sorafenib-treated hepatocellular carcinoma, FGF3/FGF4 co-amplification was detected in 3 of 10 evaluable tumors from patients with complete or partial responses and in 0… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC)

PMID 23182986 · Kim et al., 2013 · Open in CIViC

Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC)

PMID 25433983 · Jiang et al., 2015 · Open in CIViC

Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and… (full text at CIViC)

PMID 24302556 · Malchers et al., 2014 · Open in CIViC

Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF an… (full text at CIViC)

PMID 16454808 · Hase et al., 2006 · Open in CIViC

This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. The authors conclude that evidence was found for prognostic value of FGFR1 expression in cancer-associated fibro… (full text at CIViC)

PMID 26115874 · Ipenburg et al., 2016 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored the FGFR1 S602F kinase-domain mutation achieved a complete response. FGFR1 S602F was … (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

NIH-3T3 cells with the FGFR2 K660E kinase domain mutation demonstrated an increase in colony formation relative to wild-type in an anchorage-independence assay, which was lost with the introduction of… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR2 M538I achieved a partial response. The same tumor also harbored FGFR4 G665E, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

Only 12/118(10.2%) of patients with type I papillary renal cell carcinoma expressed FGFR2 whereas 37/96 (38.5%) patients with type II papillary renal cell carcinoma(P=0.001). In addition, FGFR2 expre… (full text at CIViC)

PMID 27379982 · Tsimafeyeu et al., 2017 · Open in CIViC

Patients with high FGFR2 expression had an overall survival rate of 72.2,40.6% at 1,3 years (p<0.05) and those with low FGFR2 expression had a 1,3 year survival rate of 92.0,82.8% (p<0.05). The diseas… (full text at CIViC)

PMID 20798558 · Harimoto et al., 2010 · Open in CIViC

FGFR2 p.P253R mutation detected in patient with head and neck SCC. Mutation initially detected by RNA-Seq and confirmed by Sanger sequencing. Patient is 52 y/o male with initial diagnosis of SCC of … (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR2 S320C extracellular domain mutation demonstrated an increase in colony formation in an anchorage-independence assay, which was lost with the introduction of AP24534, BGJ39… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC